{"id":"anidulafungin-and-voriconazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated liver enzymes (ALT/AST)"},{"rate":null,"effect":"Visual disturbances"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL264241","moleculeType":"Small molecule","molecularWeight":"1140.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anidulafungin is an echinocandin that disrupts the structural integrity of the fungal cell wall by inhibiting β-1,3-glucan synthase, leading to cell lysis and death. Voriconazole is a triazole that blocks ergosterol synthesis by inhibiting fungal CYP51, disrupting cell membrane function. This combination targets two distinct mechanisms of fungal cell integrity, providing synergistic activity against a wide range of fungal pathogens.","oneSentence":"Anidulafungin inhibits fungal cell wall synthesis by targeting β-1,3-glucan synthase, while voriconazole inhibits fungal cytochrome P450-dependent sterol synthesis, together providing broad-spectrum antifungal coverage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:49.528Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Invasive candidiasis"},{"name":"Invasive aspergillosis"},{"name":"Other serious fungal infections in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT01686607","phase":"","title":"Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-10-01","conditions":"Systemic Fungal Infections","enrollment":40110},{"nctId":"NCT04876716","phase":"PHASE3","title":"Azole-echinocandin Combination Therapy for Invasive Aspergillosis","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2021-05-11","conditions":"Invasive Aspergillosis","enrollment":66},{"nctId":"NCT01188759","phase":"PHASE3","title":"Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2012-05","conditions":"Aspergillosis, Invasive Pulmonary Aspergillosis, Neuroaspergillosis","enrollment":""},{"nctId":"NCT00531479","phase":"PHASE3","title":"Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-07","conditions":"Aspergillosis","enrollment":459},{"nctId":"NCT00496197","phase":"PHASE4","title":"Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-07","conditions":"Candidiasis","enrollment":282},{"nctId":"NCT00689338","phase":"PHASE3","title":"Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-07","conditions":"Invasive Candidiasis","enrollment":216},{"nctId":"NCT00548262","phase":"PHASE4","title":"This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-02","conditions":"Candidemia, Invasive Candidiasis","enrollment":54},{"nctId":"NCT00620074","phase":"PHASE4","title":"Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-08","conditions":"Aspergillosis","enrollment":6},{"nctId":"NCT00940017","phase":"PHASE4","title":"A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Aspergillosis, Candidemia","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"anidulafungin and voriconazole","genericName":"anidulafungin and voriconazole","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anidulafungin inhibits fungal cell wall synthesis by targeting β-1,3-glucan synthase, while voriconazole inhibits fungal cytochrome P450-dependent sterol synthesis, together providing broad-spectrum antifungal coverage. Used for Invasive candidiasis, Invasive aspergillosis, Other serious fungal infections in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}